drugset / Trial / NCT07363057
A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors
RandomizedParallel-groupSingle-blindTreatment
Summary
This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.
Timeline
- Start
- 2026-01
- Primary completion
- 2026-05
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GI-102 | Protein / enzyme biologic | — | Intravenous |
| Subject | GIB-7 | Other / unclassified | — | Oral |
Indications
No indication recorded.